Cargando…

Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice

Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic transgenic Glu(CreERT2);ROSA26-eYFP and Ins1...

Descripción completa

Detalles Bibliográficos
Autores principales: Lafferty, Ryan A., Tanday, Neil, Moffett, R. Charlotte, Reimann, Frank, Gribble, Fiona M., Flatt, Peter R., Irwin, Nigel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949013/
https://www.ncbi.nlm.nih.gov/pubmed/33716983
http://dx.doi.org/10.3389/fendo.2021.633625
_version_ 1783663472434741248
author Lafferty, Ryan A.
Tanday, Neil
Moffett, R. Charlotte
Reimann, Frank
Gribble, Fiona M.
Flatt, Peter R.
Irwin, Nigel
author_facet Lafferty, Ryan A.
Tanday, Neil
Moffett, R. Charlotte
Reimann, Frank
Gribble, Fiona M.
Flatt, Peter R.
Irwin, Nigel
author_sort Lafferty, Ryan A.
collection PubMed
description Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic transgenic Glu(CreERT2);ROSA26-eYFP and Ins1 (Cre/+);Rosa26-eYFP mouse models have been used to study effects of sustained NPYR1 activation on islet cell composition and alpha- and beta-cell lineage transitioning. STZ induced a particularly severe form of diabetes in Ins1 (Cre/+);Rosa26-eYFP mice, but twice-daily administration (25 nmol/kg) of SL-PYY(1-36) for 11 days consistently improved metabolic status. Blood glucose was decreased (p < 0.05 - p < 0.001) and both fasted plasma and pancreatic insulin significantly increased by SL-PYY(1-36). In both Glu(CreERT2);ROSA26-eYFP and Ins1 (Cre/+); Rosa26-eYFP mice, STZ provoked characteristic losses (p < 0.05 - p < 0.001) of islet numbers, beta-cell and pancreatic islet areas together with increases in area and central islet location of alpha-cells. With exception of alpha-cell area, these morphological changes were fully, or partially, returned to non-diabetic control levels by SL-PYY(1-36). Interestingly, STZ apparently triggered decreased (p < 0.001) alpha- to beta-cell transition in Glu(CreERT2);ROSA26-eYFP mice, together with increased loss of beta-cell identity in Ins1 (Cre/+);Rosa26-eYFP mice, but both effects were significantly (p < 0.001) reversed by SL-PYY(1-36). SL-PYY(1-36) also apparently reduced (p < 0.05) beta- to alpha-cell conversion in Ins1 (Cre/+);Rosa26-eYFP mice and glucagon expressing alpha-cells in Glu(CreERT2);ROSA26-eYFP mice. These data indicate that islet benefits of prolonged NPY1R activation, and especially restoration of beta-cell mass, are observed irrespective of diabetes status, being linked to cell lineage alterations including transdifferentiation of alpha- to beta-cells.
format Online
Article
Text
id pubmed-7949013
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79490132021-03-12 Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice Lafferty, Ryan A. Tanday, Neil Moffett, R. Charlotte Reimann, Frank Gribble, Fiona M. Flatt, Peter R. Irwin, Nigel Front Endocrinol (Lausanne) Endocrinology Enzymatically stable and specific neuropeptide Y1 receptor (NPYR1) agonists, such as sea lamprey PYY(1-36) (SL-PYY(1-36)), are believed to improve glucose regulation in diabetes by targeting pancreatic islets. In this study, streptozotocin (STZ) diabetic transgenic Glu(CreERT2);ROSA26-eYFP and Ins1 (Cre/+);Rosa26-eYFP mouse models have been used to study effects of sustained NPYR1 activation on islet cell composition and alpha- and beta-cell lineage transitioning. STZ induced a particularly severe form of diabetes in Ins1 (Cre/+);Rosa26-eYFP mice, but twice-daily administration (25 nmol/kg) of SL-PYY(1-36) for 11 days consistently improved metabolic status. Blood glucose was decreased (p < 0.05 - p < 0.001) and both fasted plasma and pancreatic insulin significantly increased by SL-PYY(1-36). In both Glu(CreERT2);ROSA26-eYFP and Ins1 (Cre/+); Rosa26-eYFP mice, STZ provoked characteristic losses (p < 0.05 - p < 0.001) of islet numbers, beta-cell and pancreatic islet areas together with increases in area and central islet location of alpha-cells. With exception of alpha-cell area, these morphological changes were fully, or partially, returned to non-diabetic control levels by SL-PYY(1-36). Interestingly, STZ apparently triggered decreased (p < 0.001) alpha- to beta-cell transition in Glu(CreERT2);ROSA26-eYFP mice, together with increased loss of beta-cell identity in Ins1 (Cre/+);Rosa26-eYFP mice, but both effects were significantly (p < 0.001) reversed by SL-PYY(1-36). SL-PYY(1-36) also apparently reduced (p < 0.05) beta- to alpha-cell conversion in Ins1 (Cre/+);Rosa26-eYFP mice and glucagon expressing alpha-cells in Glu(CreERT2);ROSA26-eYFP mice. These data indicate that islet benefits of prolonged NPY1R activation, and especially restoration of beta-cell mass, are observed irrespective of diabetes status, being linked to cell lineage alterations including transdifferentiation of alpha- to beta-cells. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7949013/ /pubmed/33716983 http://dx.doi.org/10.3389/fendo.2021.633625 Text en Copyright © 2021 Lafferty, Tanday, Moffett, Reimann, Gribble, Flatt and Irwin http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Lafferty, Ryan A.
Tanday, Neil
Moffett, R. Charlotte
Reimann, Frank
Gribble, Fiona M.
Flatt, Peter R.
Irwin, Nigel
Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
title Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
title_full Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
title_fullStr Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
title_full_unstemmed Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
title_short Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
title_sort positive effects of npy1 receptor activation on islet structure are driven by pancreatic alpha- and beta-cell transdifferentiation in diabetic mice
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7949013/
https://www.ncbi.nlm.nih.gov/pubmed/33716983
http://dx.doi.org/10.3389/fendo.2021.633625
work_keys_str_mv AT laffertyryana positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice
AT tandayneil positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice
AT moffettrcharlotte positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice
AT reimannfrank positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice
AT gribblefionam positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice
AT flattpeterr positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice
AT irwinnigel positiveeffectsofnpy1receptoractivationonisletstructurearedrivenbypancreaticalphaandbetacelltransdifferentiationindiabeticmice